文献速递神经肿瘤

阿替利珠单抗在复发性胶质母细胞瘤患者中的临床活性与安全性

Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
PubMed 文献 · J Neurooncol · 2018-08-02

本研究为1a期PCD4989g临床试验(NCT01375842)的一部分,纳入16例复发性胶质母细胞瘤患者,每3周静脉给予阿替利珠单抗1200 mg。结果显示治疗相关事件发生率为63%,无治疗相关4-5级事件,1例部分缓解(持续5.3个月),3例疾病稳定,中位总生存期4.2个月(范围1.2至18.8+个月)。作者认为阿替利珠单抗安全且耐受良好,外周血CD4+ T细胞及超突变肿瘤状态等生物标志物可能有助于筛选获益患者。

要点

  • 16例复发性胶质母细胞瘤患者接受阿替利珠单抗1200 mg每3周一次治疗。
  • 1例部分缓解(5.3个月),3例疾病稳定,中位总生存期4.2个月(范围1.2至18.8+个月)。
  • 治疗相关事件发生率63%,无治疗相关4-5级事件。

核心结论

  • 阿替利珠单抗在该组复发性胶质母细胞瘤患者中安全且耐受良好。
  • 作者初步发现提示,包括外周血CD4+ T细胞和超突变肿瘤状态在内的生物标志物可能有助于筛选最可能从阿替利珠单抗治疗中获益的复发性胶质母细胞瘤患者,支持进一步开展阿替利珠单抗联合研究。

研究设计与样本

  • 1a期PCD4989g临床试验(NCT01375842)的一部分。
  • 纳入经确诊的复发性胶质母细胞瘤且符合RANO标准可测量疾病的患者。
  • 阿替利珠单抗1200 mg静脉给药,每3周一次,直至疾病进展或不可接受的毒性。
  • 监测安全性,至少每6周评估一次疗效,并评估基线生物标志物。

主要发现

  • 全部16例入组患者均接受过既往化疗,50%接受过既往贝伐珠单抗治疗。
  • 10例患者(63%)发生治疗相关事件,未报告治疗相关4-5级事件。
  • 所有死亡均因疾病进展或发生在随访期间。
  • 1例患者达到部分缓解(持续5.3个月),3例患者疾病稳定。
  • 中位总生存期为4.2个月(范围1.2至18.8+个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioblastoma is the most common primary malignant brain tumor. No standard treatment exists for recurrent disease. Glioblastoma is associated with an immunosuppressive tumor microenvironment. Immune checkpoint inhibitors, including atezolizumab (anti-programmed death-ligand 1), have demonstrated clinical activity in various cancers. Here, we present the safety and efficacy of atezolizumab in patients with glioblastoma from the phase 1a PCD4989g clinical trial (NCT01375842). METHODS: Eligible patients had confirmed recurrent glioblastoma and measurable disease per RANO criteria. Atezolizumab (1200 mg) was administered intravenously every 3 weeks until progression or unacceptable toxicity. Patients were monitored for safety; response was evaluated at least every 6 weeks. Baseline biomarkers were evaluated. RESULTS: All 16 patients enrolled had received prior chemotherapy, and 50% prior bevacizumab. Ten patients (63%) experienced a treatment-related event. No treatment-related grade 4-5 events were reported. All deaths occurred due to progression or during follow-up. One patient experienced a partial response (5.3 months); 3 experienced disease stabilization. The median overall survival was 4.2 months (range 1.2 to 18.8+ months). Association between peripheral CD4+ T cells and efficacy was observed. Two patients with IDH1-mutant tumors and 1 with a POLE-mutant tumor experienced ≥ 16 months survival. CONCLUSIONS: Atezolizumab was safe and well tolerated in this group of patients with recurrent glioblastoma. Our preliminary findings suggest that biomarkers, including peripheral CD4+ T cells and hypermutated tumor status, may help guide selection of patients with recurrent glioblastoma who might receive most benefit from atezolizumab therapy, supporting further atezolizumab combination studies in glioblastoma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lukas RV, Rodon J, Becker K, et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018. PMID: 30073642. doi:10.1007/s11060-018-2955-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。